Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion

Janux Therapeutics (JANX) Financials

Janux Therapeutics logo
$14.52 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$14.51 -0.01 (-0.07%)
As of 05/22/2026 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Janux Therapeutics

Annual Income Statements for Janux Therapeutics

This table shows Janux Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -8.73 -33 -63 -58 -69 -114
Consolidated Net Income / (Loss)		 -6.78 -33 -63 -58 -69 -114
Net Income / (Loss) Continuing Operations		 -8.73 -33 -63 -58 -69 -114
Total Pre-Tax Income 		-8.73 -33 -63 -58 -69 -114
Total Operating Income		 -4.84 -33 -67 -73 -99 -158
Total Gross Profit		 0.00 3.64 8.61 8.08 11 10
Total Revenue		 0.00 3.64 8.61 8.08 11 10
Operating Revenue		 0.00 3.64 8.61 8.08 11 10
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 4.84 37 76 81 109 168
Selling, General & Admin Expense		 1.80 10 22 26 41 42
Research & Development Expense		 3.04 26 53 55 68 126
Total Other Income / (Expense), net		 -3.88 0.26 4.03 15 30 44
Interest & Investment Income		 0.00 0.26 4.03 15 30 44
Basic Earnings per Share		 ($7.41) ($1.39) ($1.52) ($1.32) ($1.28) ($1.83)
Weighted Average Basic Shares Outstanding		 915.15K 23.53M 41.47M 44.02M 53.75M 61.97M
Diluted Earnings per Share		 ($7.41) ($1.39) ($1.52) ($1.32) ($1.28) ($1.83)
Weighted Average Diluted Shares Outstanding		 915.15K 23.53M 41.47M 44.02M 53.75M 61.97M
Weighted Average Basic & Diluted Shares Outstanding		 915.15K 23.53M 41.83M 51.66M 59.11M 60.83M

Quarterly Income Statements for Janux Therapeutics

This table shows Janux Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -12 -12 -15 -5.96 -28 -20 -24 -34 -24 -32 -24
Consolidated Net Income / (Loss)		 -12 -12 -15 -5.96 -28 -20 -24 -34 -24 -32 -24
Net Income / (Loss) Continuing Operations		 -12 -12 -15 -5.96 -28 -20 -24 -34 -24 -32 -24
Total Pre-Tax Income 		-12 -12 -15 -5.96 -28 -20 -24 -34 -24 -32 -24
Total Operating Income		 -16 -16 -20 -14 -36 -29 -35 -45 -35 -42 -34
Total Gross Profit		 2.52 2.46 1.25 8.90 0.44 - 0.00 0.00 10 - 3.73
Total Revenue		 2.52 2.46 1.25 8.90 0.44 - 0.00 0.00 10 - 3.73
Operating Revenue		 2.52 2.46 1.25 8.90 0.44 - 0.00 0.00 10 - 3.73
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 18 19 21 23 36 29 35 45 45 42 38
Selling, General & Admin Expense		 6.44 6.36 7.34 7.82 18 8.22 9.84 10 11 11 11
Research & Development Expense		 12 12 14 15 19 21 25 35 35 32 27
Total Other Income / (Expense), net		 4.25 4.38 5.40 7.86 7.78 8.81 11 11 11 10 9.85
Interest & Investment Income		 4.25 4.38 5.40 7.86 7.78 8.81 11 11 11 10 9.85
Basic Earnings per Share		 ($0.25) ($0.23) ($0.30) ($0.11) ($0.51) ($0.36) ($0.38) ($0.55) ($0.39) ($0.51) ($0.39)
Weighted Average Basic Shares Outstanding		 45.71M 44.02M 49.05M 54.45M 54.63M 53.75M 61.79M 61.90M 62.02M 61.97M 62.67M
Diluted Earnings per Share		 ($0.25) ($0.23) ($0.30) ($0.11) ($0.51) ($0.36) ($0.38) ($0.55) ($0.39) ($0.51) ($0.39)
Weighted Average Diluted Shares Outstanding		 45.71M 44.02M 49.05M 54.45M 54.63M 53.75M 61.79M 61.90M 62.02M 61.97M 62.67M
Weighted Average Basic & Diluted Shares Outstanding		 46.17M 51.66M 51.85M 52.16M 52.48M 59.11M 59.18M 60.09M 60.15M 60.83M 60.98M

Annual Cash Flow Statements for Janux Therapeutics

This table details how cash moves in and out of Janux Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 7.16 29 16 -32 411 -378
Net Cash From Operating Activities		 -4.37 -17 -43 -51 -44 -82
Net Cash From Continuing Operating Activities		 -4.37 -17 -43 -51 -44 -82
Net Income / (Loss) Continuing Operations		 -6.78 -33 -63 -58 -69 -114
Consolidated Net Income / (Loss)		 -6.78 -33 -63 -58 -69 -114
Depreciation Expense		 0.01 0.11 0.84 1.96 2.06 2.03
Amortization Expense		 0.00 -0.17 -2.18 -7.69 -11 -18
Non-Cash Adjustments To Reconcile Net Income		 2.01 6.91 17 20 33 40
Changes in Operating Assets and Liabilities, net		 0.39 8.84 4.28 -6.55 0.69 6.71
Net Cash From Investing Activities		 0.00 -341 58 -41 -258 -301
Net Cash From Continuing Investing Activities		 0.00 -341 58 -41 -258 -301
Purchase of Property, Plant & Equipment		 0.00 -1.48 -6.45 -1.85 -0.36 -1.04
Purchase of Investments		 0.00 -474 -294 -317 -471 -705
Sale and/or Maturity of Investments		 0.00 134 359 278 213 405
Net Cash From Financing Activities		 12 387 0.50 60 713 4.95
Net Cash From Continuing Financing Activities		 12 387 0.50 60 713 4.95
Issuance of Common Equity		 0.00 204 0.00 57 698 -0.35
Other Financing Activities, net		 0.07 1.81 0.50 3.02 15 5.29

Quarterly Cash Flow Statements for Janux Therapeutics

This table details how cash moves in and out of Janux Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -17 2.05 194 -198 12 404 -357 -21 -4.06 3.95 -0.51
Net Cash From Operating Activities		 -12 -9.90 -15 -10 -2.23 -17 -17 -24 -13 -29 -12
Net Cash From Continuing Operating Activities		 -12 -9.90 -15 -10 -2.23 -17 -17 -24 -13 -29 -12
Net Income / (Loss) Continuing Operations		 -12 -12 -15 -5.96 -28 -20 -24 -34 -24 -32 -24
Consolidated Net Income / (Loss)		 -12 -12 -15 -5.96 -28 -20 -24 -34 -24 -32 -24
Depreciation Expense		 0.50 0.53 0.53 0.51 0.51 0.51 0.52 0.54 0.50 0.47 0.47
Amortization Expense		 -2.11 -2.06 -1.79 -2.97 -2.90 -2.93 -4.22 -5.21 -4.62 -3.52 -2.62
Non-Cash Adjustments To Reconcile Net Income		 4.55 4.48 5.63 5.76 15 6.25 11 11 9.04 9.52 9.27
Changes in Operating Assets and Liabilities, net		 -3.08 -1.10 -4.45 -7.35 13 -0.35 -0.52 3.75 6.54 -3.06 4.91
Net Cash From Investing Activities		 -61 11 -114 -191 13 34 -340 1.56 8.31 30 8.29
Net Cash From Continuing Investing Activities		 -61 11 -114 -191 13 34 -340 1.56 8.31 30 8.29
Purchase of Property, Plant & Equipment		 -0.47 -0.52 -0.20 -0.10 -0.03 -0.04 -0.37 -0.47 -0.09 -0.11 -0.27
Purchase of Investments		 -136 -33 -179 -236 -32 -24 -371 -93 -118 -123 -113
Sale and/or Maturity of Investments		 75 45 65 45 45 58 31 95 126 153 121
Net Cash From Financing Activities		 57 0.83 322 2.77 1.65 387 0.55 0.95 0.49 2.94 3.55
Net Cash From Continuing Financing Activities		 57 0.83 322 2.77 1.65 387 0.55 0.95 0.49 2.94 3.55
Repurchase of Common Equity		 - - - - - - -0.35 - - - 0.00
Other Financing Activities, net		 0.08 0.83 1.66 3.22 1.65 8.44 0.90 0.95 0.49 2.94 3.55

Annual Balance Sheets for Janux Therapeutics

This table presents Janux Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 16 380 364 380 1,062 1,002
Total Current Assets		 16 377 332 349 1,034 976
Cash & Equivalents		 7.81 36 51 19 431 52
Short-Term Investments		 0.00 339 276 325 595 914
Accounts Receivable		 8.00 - - - - 0.00
Prepaid Expenses		 0.25 2.05 5.42 5.21 8.49 9.32
Plant, Property, & Equipment, net		 0.16 1.41 7.09 7.00 4.86 3.85
Total Noncurrent Assets		 0.00 1.39 24 24 23 22
Other Noncurrent Operating Assets		 0.00 1.39 24 24 23 22
Total Liabilities & Shareholders' Equity		 16 380 364 380 1,062 1,002
Total Liabilities		 9.23 13 43 36 39 45
Total Current Liabilities		 3.18 13 17 13 17 25
Accounts Payable		 0.43 2.46 2.16 2.42 4.03 4.97
Accrued Expenses		 0.75 3.78 8.18 7.39 12 18
Current Deferred Revenue		 1.95 5.16 5.41 1.71 - 0.00
Other Current Liabilities		 0.05 1.40 0.76 1.52 1.75 2.39
Total Noncurrent Liabilities		 6.05 0.70 27 23 21 20
Noncurrent Deferred Revenue		 6.05 0.70 2.22 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 - 0.00 25 23 21 20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -15 366 321 344 1,023 957
Total Preferred & Common Equity		 -15 366 321 344 1,023 957
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -15 366 321 344 1,023 957
Common Stock		 0.10 414 433 512 1,258 1,304
Retained Earnings		 -15 -47 -110 -169 -238 -351
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.27 -1.54 0.67 2.16 4.32

Quarterly Balance Sheets for Janux Therapeutics

This table presents Janux Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 376 353 342 387 689 691 695 1,051 1,032 1,025 1,028
Total Current Assets		 344 321 309 355 659 662 666 1,023 1,006 998 1,002
Cash & Equivalents		 65 30 34 17 213 15 27 74 52 48 52
Short-Term Investments		 274 287 270 333 439 632 631 940 944 941 905
Accounts Receivable		 0.50 0.75 - - 0.52 7.50 - - - - 35
Prepaid Expenses		 5.07 3.77 6.01 5.48 6.38 8.15 8.29 9.19 9.54 9.09 11
Plant, Property, & Equipment, net		 6.51 7.20 7.38 7.32 6.52 5.94 5.37 4.95 4.69 4.31 3.55
Total Noncurrent Assets		 25 24 25 24 24 24 23 22 22 22 23
Other Noncurrent Operating Assets		 25 24 25 24 24 24 23 22 22 22 23
Total Liabilities & Shareholders' Equity		 376 353 342 387 689 691 695 1,051 1,032 1,025 1,028
Total Liabilities		 44 42 42 38 33 34 39 38 42 48 87
Total Current Liabilities		 16 16 18 14 11 12 17 18 21 28 59
Accounts Payable		 2.87 2.05 1.91 2.51 2.25 1.25 2.46 2.35 3.48 3.40 3.38
Accrued Expenses		 7.24 7.74 9.22 6.83 5.81 8.57 13 13 16 22 15
Current Deferred Revenue		 5.91 4.94 5.34 3.65 0.97 0.09 0.00 0.00 0.00 0.00 38
Other Current Liabilities		 0.32 1.39 1.44 1.49 1.57 1.63 1.69 1.81 1.87 2.28 2.47
Total Noncurrent Liabilities		 28 26 24 23 23 22 22 21 20 20 28
Noncurrent Deferred Revenue		 3.82 1.39 0.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.68
Other Noncurrent Operating Liabilities		 24 24 24 23 23 22 22 21 20 20 19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 332 311 299 349 656 658 656 1,012 991 977 942
Total Preferred & Common Equity		 332 311 299 349 656 658 656 1,012 991 977 942
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 332 311 299 349 656 658 656 1,012 991 977 942
Common Stock		 428 440 446 507 840 849 866 1,270 1,282 1,291 1,317
Retained Earnings		 -94 -128 -145 -157 -184 -189 -218 -261 -295 -319 -376
Accumulated Other Comprehensive Income / (Loss)		 -2.28 -0.74 -1.06 -1.18 -0.52 -1.62 7.83 3.76 3.75 4.56 0.58

Annual Metrics And Ratios for Janux Therapeutics

This table displays calculated financial ratios and metrics derived from Janux Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 136.79% -6.14% 30.99% -5.55%
EBITDA Growth		 0.00% -287.82% -107.45% -15.02% -36.41% -61.32%
EBIT Growth		 0.00% -286.54% -103.74% -8.78% -35.45% -59.51%
NOPAT Growth		 0.00% -579.93% -103.74% -8.78% -35.45% -59.51%
Net Income Growth		 0.00% -381.60% -93.01% 7.56% -18.36% -64.69%
EPS Growth		 0.00% 81.24% -9.35% 13.16% 3.03% -42.97%
Operating Cash Flow Growth		 0.00% -288.56% -152.84% -17.83% 13.37% -87.69%
Free Cash Flow Firm Growth		 0.00% 0.00% -223.67% -16.94% -15.25% -54.96%
Invested Capital Growth		 0.00% -944.50% 27.34% 105.11% -845.17% -307.40%
Revenue Q/Q Growth		 0.00% 0.00% 16.65% -4.54% -18.86% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -9.04% 1.86% -14.71% -8.81%
EBIT Q/Q Growth		 0.00% 0.00% -7.66% 2.83% -14.99% -9.27%
NOPAT Q/Q Growth		 0.00% 0.00% -7.66% 2.83% -14.99% -9.27%
Net Income Q/Q Growth		 0.00% 0.00% -4.39% 6.88% -13.97% -11.51%
EPS Q/Q Growth		 0.00% 0.00% -461.90% 10.81% -11.30% -8.93%
Operating Cash Flow Q/Q Growth		 0.00% -108.96% -3.45% 3.83% -18.45% -16.78%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 2.33% -12.66% -13.84%
Invested Capital Q/Q Growth		 0.00% 0.00% 13.40% 142.02% -24.13% 21.65%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% -907.01% -794.62% -973.80% -1,014.09% -1,732.12%
Operating Margin		 0.00% -905.39% -779.04% -902.87% -933.58% -1,576.67%
EBIT Margin		 0.00% -905.39% -779.04% -902.87% -933.58% -1,576.67%
Profit (Net Income) Margin		 0.00% -898.32% -732.22% -721.18% -651.62% -1,136.25%
Tax Burden Percent		 77.75% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 102.42% 99.22% 93.99% 79.88% 69.80% 72.07%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -97.11% -17.50% -18.36% -17.53% -10.09% -11.48%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -17,969.56% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -16.63% -18.04% -19.61% -13.71% -15.28%
Return on Assets (ROA)		 0.00% -16.50% -16.96% -15.66% -9.57% -11.02%
Return on Common Equity (ROCE)		 203.47% -16.49% -18.36% -17.53% -10.09% -11.48%
Return on Equity Simple (ROE_SIMPLE)		 46.35% -8.92% -19.66% -16.93% -6.75% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.39 -23 -47 -51 -69 -110
NOPAT Margin		 0.00% -633.77% -545.33% -632.01% -653.50% -1,103.67%
Net Nonoperating Expense Percent (NNEP)		 -43.44% -5.03% -4.59% -2.15% 0.03% -0.33%
Return On Investment Capital (ROIC_SIMPLE)		 - - -14.64% -14.84% -6.77% -11.53%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 284.00% 258.50% 323.39% 387.67% 417.71%
R&D to Revenue		 0.00% 721.39% 620.54% 679.48% 645.90% 1,258.96%
Operating Expenses to Revenue		 0.00% 1,005.39% 879.04% 1,002.87% 1,033.58% 1,676.67%
Earnings before Interest and Taxes (EBIT)		 -8.52 -33 -67 -73 -99 -158
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.51 -33 -68 -79 -107 -173
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 2.24 1.71 1.44 2.75 0.87
Price to Tangible Book Value (P/TBV)		 0.00 2.24 1.71 1.44 2.75 0.87
Price to Revenue (P/Rev)		 0.00 225.73 63.71 61.29 265.38 83.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 471.52 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 122.64 25.74 18.73 168.56 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.12 -1.03 -1.02 -1.01 -1.00 -1.01
Leverage Ratio		 2.32 1.06 1.08 1.12 1.05 1.04
Compound Leverage Factor		 2.38 1.05 1.02 0.89 0.74 0.75
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 309.53% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -209.53% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 10.54 37.20 7.64 8.07 44.06 11.27
Noncontrolling Interest Sharing Ratio		 309.53% 5.79% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 5.05 29.46 20.14 26.80 59.21 39.04
Quick Ratio		 4.97 29.30 19.81 26.40 58.72 38.67
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -15 -49 -58 -66 -103
Operating Cash Flow to CapEx		 0.00% -1,145.48% -665.97% -2,733.78% -12,204.46% -7,884.47%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -21.21 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -21.21 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.02 0.02 0.02 0.01 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 4.64 2.03 1.15 1.78 2.29
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -0.83 -8.64 -6.28 0.32 -2.39 -9.75
Invested Capital Turnover		 0.00 -0.77 -1.15 -2.71 -10.23 -1.65
Increase / (Decrease) in Invested Capital		 0.00 -7.81 2.36 6.60 -2.71 -7.35
Enterprise Value (EV)		 208 446 222 151 1,785 -137
Market Capitalization		 194 821 549 495 2,810 830
Book Value per Share		 ($16.00) $8.80 $7.70 $7.46 $19.49 $15.91
Tangible Book Value per Share		 ($16.00) $8.80 $7.70 $7.46 $19.49 $15.91
Total Capital		 6.99 366 321 344 1,023 957
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -7.81 -375 -327 -344 -1,025 -967
Capital Expenditures (CapEx)		 0.00 1.48 6.45 1.85 0.36 1.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 5.07 -11 -11 -7.82 -8.97 -16
Debt-free Net Working Capital (DFNWC)		 13 364 316 336 1,016 951
Net Working Capital (NWC)		 13 364 316 336 1,016 951
Net Nonoperating Expense (NNE)		 3.39 9.62 16 7.21 -0.20 3.26
Net Nonoperating Obligations (NNO)		 -7.81 -375 -327 -344 -1,025 -967
Total Depreciation and Amortization (D&A)		 0.01 -0.06 -1.34 -5.73 -8.53 -16
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -295.38% -128.70% -96.75% -84.68% -156.77%
Debt-free Net Working Capital to Revenue		 0.00% 10,014.35% 3,668.51% 4,159.45% 9,597.72% 9,508.90%
Net Working Capital to Revenue		 0.00% 10,014.35% 3,668.51% 4,159.45% 9,597.72% 9,508.90%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.39) ($1.52) ($1.32) ($1.28) ($1.83)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 41.62M 41.47M 44.02M 53.75M 61.97M
Adjusted Diluted Earnings per Share		 $0.00 ($1.39) ($1.52) ($1.32) ($1.28) ($1.83)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 41.62M 41.47M 44.02M 53.75M 61.97M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.39) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 23.53M 41.83M 51.66M 59.11M 60.83M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.39 -23 -47 -51 -69 -110
Normalized NOPAT Margin		 0.00% -633.77% -545.33% -632.01% -653.50% -1,103.67%
Pre Tax Income Margin		 0.00% -898.32% -732.22% -721.18% -651.62% -1,136.25%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -41.35 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -16.46 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -41.35 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -16.46 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Janux Therapeutics

This table displays calculated financial ratios and metrics derived from Janux Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 60,831,656.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 60,831,656.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.40
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 38.83% -13.50% -38.87% 741.72% -82.56% 0.00% -100.00% -100.00% 2,177.90% 0.00% 0.00%
EBITDA Growth		 6.04% 7.77% 0.42% 26.35% -119.45% -77.94% -80.23% -205.62% -2.99% -44.60% 5.78%
EBIT Growth		 12.26% 11.66% 0.59% 33.38% -126.66% -79.85% -73.09% -226.42% 1.65% -46.10% 1.96%
NOPAT Growth		 12.26% 11.66% 0.59% 33.38% -126.66% -79.85% -73.09% -226.42% 1.65% -46.10% 1.96%
Net Income Growth		 30.71% 26.81% 15.46% 65.96% -142.56% -71.93% -59.27% -468.18% 13.35% -58.02% -3.63%
EPS Growth		 37.50% 41.03% 28.57% 73.81% -104.00% -56.52% -26.67% -400.00% 23.53% -41.67% -2.63%
Operating Cash Flow Growth		 12.71% 16.89% -6.66% 33.43% 80.95% -68.92% -14.74% -137.63% -476.24% -70.65% 27.53%
Free Cash Flow Firm Growth		 -8.85% -18.12% -63.39% -17.44% -36.32% 1.62% 20.96% 40.90% 40.80% -26.84% 42.54%
Invested Capital Growth		 89.46% 105.11% 171.29% 398.01% -152.23% -845.17% -141.93% -148.27% -545.46% -307.40% -785.57%
Revenue Q/Q Growth		 138.13% -2.22% -49.13% 610.62% -95.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 21.24% -1.41% -21.22% 23.94% -134.70% 17.77% -22.78% -28.97% 20.91% -15.45% 19.99%
EBIT Q/Q Growth		 23.79% -2.05% -24.94% 31.44% -159.31% 19.03% -20.24% -29.29% 21.87% -20.28% 19.31%
NOPAT Q/Q Growth		 23.79% -2.05% -24.94% 31.44% -159.31% 19.03% -20.24% -29.29% 21.87% -20.28% 19.31%
Net Income Q/Q Growth		 33.93% -1.64% -25.53% 59.63% -370.87% 27.95% -16.28% -44.03% 28.19% -31.39% 23.74%
EPS Q/Q Growth		 40.48% 8.00% -30.43% 63.33% -363.64% 29.41% -5.56% -44.74% 29.09% -30.77% 23.53%
Operating Cash Flow Q/Q Growth		 22.22% 15.44% -49.85% 32.46% 77.74% -649.66% -1.79% -39.88% 46.01% -122.01% 56.78%
Free Cash Flow Firm Q/Q Growth		 17.15% -1.94% -32.59% -4.87% 3.83% 26.43% -6.52% 21.58% 3.67% -57.63% 51.74%
Invested Capital Q/Q Growth		 80.00% 142.02% 1,146.11% 184.60% -116.93% -24.13% 29.89% -227.67% -126.35% 21.65% -52.40%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 100.00% 0.00% 100.00%
EBITDA Margin		 -692.13% -717.88% -1,710.54% -183.08% -8,708.43% 0.00% 0.00% 0.00% -393.73% 0.00% -974.23%
Operating Margin		 -628.25% -655.71% -1,610.30% -155.36% -8,164.46% 0.00% 0.00% 0.00% -352.51% 0.00% -916.50%
EBIT Margin		 -628.25% -655.71% -1,610.30% -155.36% -8,164.46% 0.00% 0.00% 0.00% -352.51% 0.00% -916.50%
Profit (Net Income) Margin		 -459.59% -477.77% -1,178.91% -66.98% -6,391.57% 0.00% 0.00% 0.00% -243.13% 0.00% -652.59%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 73.16% 72.86% 73.21% 43.11% 78.29% 69.66% 67.36% 75.04% 68.97% 75.34% 71.20%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -434.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -435.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 432.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -18.40% -17.53% -11.50% -2.66% -12.05% -10.09% 0.00% 0.00% -12.48% -11.48% -11.72%
Cash Return on Invested Capital (CROIC)		 0.00% -17,969.56% -1,515.31% -538.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -13.95% -14.24% -22.52% -4.55% -196.95% 0.00% 0.00% 0.00% -4.10% 0.00% -12.11%
Return on Assets (ROA)		 -10.21% -10.38% -16.49% -1.96% -154.18% 0.00% 0.00% 0.00% -2.83% 0.00% -8.62%
Return on Common Equity (ROCE)		 -18.40% -17.53% -11.50% -2.66% -12.05% -10.09% 0.00% 0.00% -12.48% -11.48% -11.72%
Return on Equity Simple (ROE_SIMPLE)		 -17.94% 0.00% -8.48% -6.70% -9.23% 0.00% -7.68% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -11 -14 -9.68 -25 -20 -24 -32 -25 -30 -24
NOPAT Margin		 -439.77% -459.00% -1,127.21% -108.75% -5,715.13% 0.00% 0.00% 0.00% -246.76% 0.00% -641.55%
Net Nonoperating Expense Percent (NNEP)		 -0.14% -0.14% -0.13% 0.78% -0.59% 0.01% 0.11% -0.28% 0.04% -0.23% -0.04%
Return On Investment Capital (ROIC_SIMPLE)		 - -3.28% - - - -1.99% -2.41% -3.19% -2.53% -3.10% -2.54%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 255.78% 258.31% 586.50% 87.91% 4,024.37% 0.00% 0.00% 0.00% 106.22% 0.00% 298.23%
R&D to Revenue		 472.47% 497.40% 1,123.80% 167.45% 4,240.09% 0.00% 0.00% 0.00% 346.29% 0.00% 718.27%
Operating Expenses to Revenue		 728.25% 755.71% 1,710.30% 255.36% 8,264.46% 0.00% 0.00% 0.00% 452.51% 0.00% 1,016.50%
Earnings before Interest and Taxes (EBIT)		 -16 -16 -20 -14 -36 -29 -35 -45 -35 -42 -34
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -18 -21 -16 -38 -31 -39 -50 -39 -45 -36
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.33 1.44 2.97 3.30 3.61 2.75 1.58 1.38 1.50 0.87 0.90
Price to Tangible Book Value (P/TBV)		 1.33 1.44 2.97 3.30 3.61 2.75 1.58 1.38 1.50 0.87 0.90
Price to Revenue (P/Rev)		 54.93 61.29 266.91 143.59 181.61 265.38 170.93 3,113.77 146.87 83.00 61.57
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 471.52 323.31 134.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 13.63 18.73 177.47 100.86 131.18 168.56 62.31 844.95 47.97 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.01 -1.00 -0.99 -1.00 -1.00 -1.00 -1.00 -1.01 -1.01 -1.01
Leverage Ratio		 1.12 1.12 1.08 1.08 1.08 1.05 1.04 1.05 1.05 1.04 1.06
Compound Leverage Factor		 0.82 0.82 0.79 0.47 0.84 0.73 0.70 0.78 0.73 0.79 0.76
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.74 8.56 35.80 39.33 37.07 44.28 25.70 20.27 18.87 11.65 6.34
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 24.55 26.80 62.09 57.34 38.80 59.21 58.47 47.03 35.86 39.04 17.01
Quick Ratio		 24.17 26.40 61.48 56.63 38.32 58.72 57.94 46.59 35.54 38.67 16.83
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -18 -18 -24 -25 -24 -18 -19 -15 -14 -22 -11
Operating Cash Flow to CapEx		 -2,491.28% -1,922.52% -7,531.47% -10,548.42% -8,924.00% -39,821.43% -4,588.68% -5,034.46% -13,823.66% -26,926.42% -4,519.05%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.02 0.01 0.03 0.02 0.01 0.01 0.00 0.01 0.01 0.01
Accounts Receivable Turnover		 0.00 0.00 11.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.22 1.15 1.06 2.27 2.06 1.78 1.63 0.08 2.06 2.29 3.23
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 31.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 31.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.76 0.32 4.00 11 -1.93 -2.39 -1.68 -5.50 -12 -9.75 -15
Invested Capital Turnover		 -2.11 -2.71 -9.05 4.00 -9.70 -10.23 8.04 0.15 -1.39 -1.65 -1.66
Increase / (Decrease) in Invested Capital		 6.48 6.60 9.61 15 -1.16 -2.71 -5.68 -17 -11 -7.35 -13
Enterprise Value (EV)		 115 151 1,293 1,526 1,712 1,785 582 371 480 -137 -111
Market Capitalization		 465 495 1,945 2,172 2,370 2,810 1,596 1,367 1,469 830 846
Book Value per Share		 $7.56 $7.46 $12.69 $12.68 $12.58 $19.49 $17.13 $16.74 $16.25 $15.91 $15.48
Tangible Book Value per Share		 $7.56 $7.46 $12.69 $12.68 $12.58 $19.49 $17.13 $16.74 $16.25 $15.91 $15.48
Total Capital		 349 344 656 658 656 1,023 1,012 991 977 957 942
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -350 -344 -652 -646 -658 -1,025 -1,014 -996 -989 -967 -956
Capital Expenditures (CapEx)		 0.47 0.52 0.20 0.10 0.03 0.04 0.37 0.47 0.09 0.11 0.27
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.99 -7.82 -3.71 4.10 -8.88 -8.97 -8.31 -12 -19 -16 -13
Debt-free Net Working Capital (DFNWC)		 341 336 648 650 649 1,016 1,006 984 970 951 943
Net Working Capital (NWC)		 341 336 648 650 649 1,016 1,006 984 970 951 943
Net Nonoperating Expense (NNE)		 0.50 0.46 0.65 -3.72 2.97 -0.10 -0.92 2.28 -0.36 2.27 0.41
Net Nonoperating Obligations (NNO)		 -350 -344 -652 -646 -658 -1,025 -1,014 -996 -989 -967 -956
Total Depreciation and Amortization (D&A)		 -1.61 -1.53 -1.26 -2.47 -2.39 -2.42 -3.70 -4.67 -4.12 -3.06 -2.16
Debt-free, Cash-free Net Working Capital to Revenue		 -106.15% -96.75% -50.86% 27.11% -68.07% -84.68% -89.00% -2,696.36% -187.38% -156.77% -96.50%
Debt-free Net Working Capital to Revenue		 4,024.14% 4,159.45% 8,893.33% 4,299.56% 4,974.70% 9,597.72% 10,773.75% 224,185.42% 9,702.55% 9,508.90% 6,867.65%
Net Working Capital to Revenue		 4,024.14% 4,159.45% 8,893.33% 4,299.56% 4,974.70% 9,597.72% 10,773.75% 224,185.42% 9,702.55% 9,508.90% 6,867.65%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.25) ($0.23) ($0.30) ($0.11) ($0.51) ($0.36) ($0.38) ($0.55) ($0.39) ($0.51) ($0.39)
Adjusted Weighted Average Basic Shares Outstanding		 45.71M 44.02M 49.05M 54.45M 54.63M 53.75M 61.79M 61.90M 62.02M 61.97M 62.67M
Adjusted Diluted Earnings per Share		 ($0.25) ($0.23) ($0.30) ($0.11) ($0.51) ($0.36) ($0.38) ($0.55) ($0.39) ($0.51) ($0.39)
Adjusted Weighted Average Diluted Shares Outstanding		 45.71M 44.02M 49.05M 54.45M 54.63M 53.75M 61.79M 61.90M 62.02M 61.97M 62.67M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 46.17M 51.66M 51.85M 52.16M 52.48M 59.11M 59.18M 60.09M 60.15M 60.83M 60.98M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -11 -14 -9.68 -25 -20 -24 -32 -25 -30 -24
Normalized NOPAT Margin		 -439.77% -459.00% -1,127.21% -108.75% -5,715.13% 0.00% 0.00% 0.00% -246.76% 0.00% -641.55%
Pre Tax Income Margin		 -459.59% -477.77% -1,178.91% -66.98% -6,391.57% 0.00% 0.00% 0.00% -243.13% 0.00% -652.59%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Janux Therapeutics, Inc. (NASDAQ: JANX) has shown mixed results over the last four years on a quarterly basis. Below is a concise, data-driven snapshot focused on recent quarters (2025 through the prior four-year window) that highlights cash flow, profitability, and balance-sheet trends for retail investors.

  • Investing cash flow turned positive in Q4 2025: Net cash from continuing investing activities was +$29.543 million, driven by selling/maturing investments (approx. +$152.926 million) more than purchases (approx. −$123.277 million).
  • Financing cash flow remained modestly positive in Q4 2025: Net cash from financing activities was +$2.944 million, continuing a pattern of small external funding inflows.
  • Healthy equity cushion with low leverage (Q3 2025): Total assets about $1.0246B, total equity about $0.9766B, and total liabilities around $48.2M, indicating a solid equity base relative to modest liabilities.
  • Modest topline in Q3 2025: Operating revenue of $10.0M with gross profit of $10.0M, though the company still reports operating losses.
  • Share count and earnings per share remain negative, but relatively stable: Weighted-average basic shares ~61.9M–62.0M; basic and diluted EPS around −$0.39 to −$0.55 in recent quarters.
  • Cash balance has fluctuated but remained in the tens of millions: Cash & equivalents around $48.4M in Q3 2025, down from about $73.7M in Q1 2025.
  • R&D and SG&A burn remains meaningful: R&D in the mid-$30M range and SG&A around $10–$11M per quarter in recent periods, indicating ongoing development spend.
  • Net losses persist across 2025: Consolidated net income ranges from approximately −$23.5M (Q1 2025) to −$33.9M (Q2 2025) and −$31.9M (Q4 2025).
  • Operating cash burn remains elevated: Net cash from continuing operating activities was −$28.5M (Q4 2025), −$12.9M (Q3 2025), −$23.8M (Q2 2025), and −$17.0M (Q1 2025).
  • Accumulated deficits on the balance sheet: Retained earnings negative, roughly −$319.4M (Q3 2025) and around −$261.3M (Q1 2025), reflecting ongoing cumulative losses.
05/25/26 09:54 PM ETAI Generated. May Contain Errors.

Janux Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Janux Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Janux Therapeutics' net income appears to be on an upward trend, with a most recent value of -$113.63 million in 2025, rising from -$6.78 million in 2020. The previous period was -$68.99 million in 2024. See where experts think Janux Therapeutics is headed by visiting Janux Therapeutics' forecast page.

Janux Therapeutics' total operating income in 2025 was -$157.67 million, based on the following breakdown:
  • Total Gross Profit: $10 million
  • Total Operating Expenses: $167.67 million

Over the last 5 years, Janux Therapeutics' total revenue changed from $0.00 in 2020 to $10 million in 2025, a change of 1,000,000,000.0%.

Janux Therapeutics' total liabilities were at $44.74 million at the end of 2025, a 15.5% increase from 2024, and a 384.7% increase since 2020.

In the past 5 years, Janux Therapeutics' cash and equivalents has ranged from $7.81 million in 2020 to $430.61 million in 2024, and is currently $52.33 million as of their latest financial filing in 2025.

Over the last 5 years, Janux Therapeutics' book value per share changed from -16.00 in 2020 to 15.91 in 2025, a change of -199.5%.


Related Companies

Financial statements for NASDAQ:JANX last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel